RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody HX009 shows promise for tough lymphoma cases
Disease control CompletedThis study tested a new drug called HX009 in 48 Chinese patients with lymphoma that had relapsed or not responded to prior treatments. HX009 is a dual-target antibody designed to block two proteins (CD47 and PD-1) that help cancer cells hide from the immune system. The goal was t…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Off-the-Shelf CAR t cells take on tough lymphomas
Disease control CompletedThis early-phase study tested a new type of cell therapy called ALLO-501, made from donor cells rather than the patient's own cells, in 50 adults with lymphoma that had come back or stopped responding to treatment. The therapy targets CD19, a protein on cancer cells, and was give…
Matched conditions: RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC